Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Cryoport’

Cryoport: Quick Take on 2Q Results (CYRX, $20.18, Buy)

Cryoport reported a very strong quarter as sales increased by 83%. The key biopharma segment increased sales by 81%. This was led by a 326% increase in sales stemming from support of the commercial CAR-T products, Kymriah and Yescarta. Some $600,000 of incremental sales were recorded from the acquisition of Cryogene which closed on May […]

Cryoport; Sales of CAR-T Products Yescarta and Kymriah are In-line with My Projections (CYRX, Buy, $20.67)

Cryoport will report 2Q, 2019 results on August 8, 2019 at 5:00 PM EST. One area of keen interest for investors will be sales relating to the support of the CAR-T products-Gilead’s Yescarta and Novartis’ Kymriah. Gilead has reported that Yescarta sales in 2Q, 2019 were $120 million which compares to my last published estimate […]

Cryoport: I View the Just Completed Equity Offering as a Major Positive (CYRX, Buy, $18.00)

Overview of Equity Offering Cryoport quickly and very successfully executed an equity offering after the close on June 19, 2019. It sold 3,750,000 shares at a price to investors of $17.00 per share. This was at a discount of about 9% from the closing price of $18.62. After underwriting discounts, Cryoport received $59.80 million which […]

Cryoport: Details of My Model for Sales for 2018 to 2024 (CYRX, Buy, $16.88)

Key Points: I am projecting that total sales will increase from $19.6 million in 2018 to $31.0 million in 2019 and $83.9 million in 2024. This is a fourfold increase in sales over the 2018 to 2024 period. Even though these numbers appear to be aggressive, I have tried to go out of my way […]

Cryoport: Great Buying Opportunity (CYRX. Buy, $10.44)

Quick Comment on 4Q, 2018 Sales and Earnings Report Cryoport reported a spectacular 4Q, 2018 quarter last night. Biopharma revenues which are 84% of total revenues increased 94% to $4.9 million which compared to my estimate of $4.3 million. Total revenues increased 72% to $5.7 million as compared to my estimate of $5.2 million. The […]

Cryoport: The Bristol-Myers Acquisition of Celgene is a Validation of my Investment Thesis for Cryoport (CYRX, Buy, $9.05)

Investment Thesis The proposed acquisition of Celgene by Bristol-Myers Squibb was generally panned by Wall Street investors and analysts as BMY stock dropped 14% on the news. The investment community is deeply concerned with the patent situation with Revlimid which accounts for over 60% of CELG revenues. There will be full blown generic entries in […]

Cryoport Raises a $25 Million Warchest for Acquisitions (CYRX, $9.45, Buy)

Cryoport raises $25 million warchest for acquisiitons

Cryoport: Detailed Update and Updated Projections Based on 3Q Results (CYRX, Buy, $10.35)

Key Points Cryoport continued to show explosive growth in the third quarter as sales increased 76% to $5.3 million led by a 91% increase in biopharma (83% of total) sales. I am projecting a 60% increase in sales in 2019 to $30.7 million again led by a 69% increase in biopharma. (Detailed sales and a […]

Regenerative Medicine: Thoughts on How to Invest in This Dynamic New Technology

Key Investment Points of this Report Regenerative medicines promises to be a (the) major technology driving the biopharma industry in coming decades. The CAR-T products are the first commercially significant products stemming from this technology, but they are just the tip of a very large iceberg. Novartis, Gilead and Celgene have gained first mover status […]

Cryoport: Reiterating My Buy Recommendation (CYRX, Buy, $14.20)

Investment Perspective On May 16, 2018, I published a report entitled Updated Sales and Earnings Model. The purpose of that report was to build a detailed sales model for the Company that for the first time incorporated Cryoport revenues arising from the sale of commercial products-the CAR-T drugs Kymriah and Yescarta. You may want to […]